Pharmacovigilance and PML in the oncology setting

Cleveland Clinic Journal of Medicine

Volumn 78, Issue SUPPL. 2, 2011, Pages

  Bennett, Charles L ^a  

^a UNIVERSITY OF SOUTH CAROLINA COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; RITUXIMAB;

DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; HUMAN; JC VIRUS; LYMPHOMA; PHYSIOLOGY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; VIROLOGY; VIRUS ACTIVATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; IMMUNOLOGIC FACTORS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LYMPHOMA; PHARMACOVIGILANCE; VIRUS ACTIVATION;

EID: 84859911166     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.78.s2.04     Document Type: Article

References (27)

1. Hampton T. Postmarket "pharmacovigilance" program on alert for adverse events from drugs. JAMA 2007; 298:851-852.
2. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354:911-923.
3. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein Du, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287:2215-2220.
4. Bennett CL, Nebeker JR, Lyons EA, et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA 2005; 293:2131-2140.
5. Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008; 9:1166-1172.
6. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancerassociated anemia. JAMA 2008; 299:914-924.
7. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007; 297:1992-2000.
8. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99:196-205.
9. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98:708-714.
10. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47:175-181.
11. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006; 296:2558-2560.
12. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351:1403-1408.
13. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342:1773-1777.
14. Bennett CL, Kiss JE, Weinberg PD, et al. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet 1998; 352:1036-1037.
15. Rituxan (rituximab) Oct 2004. U.S. Food and Drug Administration Web site. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm166521.htm. Updated June 19, 2009. Accessed September 13, 2011.
16. Rituxan (rituximab). U.S. Food and Drug Administration Web site. http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety AlertsforHumanMedicalProducts/ucm150747.htm. Updated June 19, 2009. Accessed September 13, 2011.
17. Carson KR, Evens AM, Richey EA, et al. Progressive multif ocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834-4840.
18. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110:2924-2930.
19. Tamimoto Y, Horiuchi T, Tsukamoto H, et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology (Oxford) 2008; 47:821-827.
20. McFarland HF. The B cell-old player, new position on the team. N Engl J Med 2008; 358:664-665.
21. Power C, Gladden JG, Halliday W, et al. AIDS- and non-AIDSrelated PML association with distinct p53 polymorphism. Neurology 2000; 54:743-746.
22. Gonzalez H, Bolgert F, Camporo P, Leblond V. Progressive multi focal leukoencephalitis (PML) in three patients treated with standard-dose fl udarabine (FAMP). Hematol Cell Ther 1999; 41:183-186.
23. Garcia-Suárez J, de Miguel D, Krsnik I, Bañas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005; 80:271-281.
24. Kavanaugh A, Matteson E. Hotline: rituximab and progressive multifocal leukoencephalopathy. American College of Rheumatology Web site. http://www.rheumatology.org/publications/ hotline/0107leuko.asp. Updated January 2007. Accessed September 13, 2011.
25. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 2008; 8:144-146.
26. Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 2008; 67(suppl 3): iii64-iii65.
27. Tuccori M, Focosi D, Blandizzi C, et al. Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist 2010; 15:1214-1219. Epub 2010 Nov 1.